Q2 2019 Earnings Call
Welcome to <unk>.
First half 2019 financial results Conference call. This call is being webcast live on the events <unk> the Investor section.
<unk> Dot com.
This call is property as average.
And any recording.
Reproduction or transmission Oh, this car without the expressed written consent.
This is strictly prohibited as a reminder, today's call is being recorded you may listen to a webcast replay of this call by going to the industry.
Busters section website Emerson's website.
I would like to now turn the conference over to Peter Dinardo Director of Investor Relations and corporate communications.
Thanks, Jay Good afternoon. Thank you for joining me today with me today or John Melo, Our Chief Executive Officer, Eduardo Alvarez, Chief operating officer, and Jonathan bolster our interim Chief Financial Officer.
No. This call you what your discussions a non-GAAP financial measures, including gross margin figures reconciliation of these non-GAAP measures to the most directly comparable GAAP financial measures is contained in the summary financial information Slide show. The accompanying presentation will be we're doing today for the first and second quarter 20.
The team.
Use of which we expect to follow shortly.
During this call we will make forward looking statements about events and circumstances, they have not yet occurred including projections that operating activities other anticipated financial impact our business and financial results for 2019 and beyond.
These statements are based on management's current expectations and actual results at future events may differ materially due to risks or uncertainties, including those detailed from time to time and Emirates makes with the Securities Exchange Commission, including annual reports on Form 10-K quarterly reports on form 10.
Current reports on form 8-K.
Everest and any obligation to update information contained in these forward looking statements whether as a result of new information future events or otherwise please refer to the Emirates SPP falling for detailed discussion of the relevant risks and uncertainties.
We began today I'd like to note that included a webcast as a slide presentation, we will refer to in todays presentation, which includes reconciliations to the figures decided today.
I'll now turn the call over to John Melo John .
Thanks Peter.
Good afternoon, Thank you for joining us today.
After months of frustration regarding our inability to file our financials in a timely manner I am pleased to finally have the opportunity to discuss our financial results openly and it's also say that we are very close to putting this painful chapter and Amherst its history behind US we filed our 10-K for 2018 and are very.
Close to filing our 10-Q's for the first and second quarters of 2019.
I want to thank our new auditors are finance and legal teams for staying on task working extremely long hours, often all day and through the night and getting near us being fully compliant.
We're going to share financial data on this call there will be reflected in our queues and we expect our views on trial very shortly we are in the final stage of review and signed off by all parties. We plan to have all of our filing its complete by Monday with everyone working extensive hours and tired we wanted to get this right.
As we've shared before the many accounting adjustments for 2017 and 2018, we're focused around so very complex transactions, mostly connected with DSME a significant related party.
These adjustments are accounting based regarding interest between the P.L. and the balance sheet and do not reflect any change to the health of our business have any impact on the cash we were paid during these periods or the quality of the business transactions. During these periods. We're very pleased for the work of our two new audit.
First he did excellent work on auditing our business.
Joining me today to review business highlights, our we'd want to Alvarez, our chief operating officer, who will discuss operational highlights and also our operational focus through the second half toward meeting our production goals and Jonathan alter our interim CFO core who will review our financial results and summarize the a job.
Turning to our historical financial results as outlined in our S. T SEC filings.
Well, let me now start by saying that we are pleased with our first half 2019 results would revenue for the period at $77.1 million compared with 32.9 million for the first half of 2018.
This concludes our doubling of recurring product revenue over the first half of 2000 $18 billion to $24 billion collaborations grandson royalty revenue of about $53 million and non-GAAP gross margin for the first half of almost 62%, which is tracking well to the.
Higher end of our guidance of 55% to 65% gross margin for the year.
Our revenue for the first half includes about $40 million and vitamin E revenue, resulting from the sale of our vitamin E value share agreement to D.S. them in the second quarter of 2019 as a result about exiting that business for which we received over $50 million in cash.
Part of revenue continues to trend towards doubling for better or what product revenue growth of about 103% for the first half of 2019 over the prior years period. This excludes anything related to bite of many and it's consistent with our strategic plan to double our recurring revenue annually.
While maintaining a solid product pipeline funded through partner collaborations.
I can also confirmed that our third quarter revenue has continued to perform very well recurring product sales in the quarter will likely be near the same as the some of the first half. The first half was mostly clean beauty in the third quarter clean beauty has continued delivering very strong.
And the ingredient business is also helping us set a product revenue record.
In the third quarter.
Our key growth drivers remain leadership, and clean beauty and health and ingredients.
Markets, the lateral which we grouped together vitamins, excluding vitamin D flavors, and fragrances and sweetener revenue to simplify the comparisons in our slide presentation for today's call.
Within clean beauty, our squealing ingredients business continues its healthy trend of almost doubling sales each year as.
As you'd water will explain shark craft, our head of manufacturing our supply team and all of our staff at our Leland production facility have done a tremendous job and supporting needed volume production squarely to deliver on the record demand from our customers.
We believe clean beauty, we'll finish the year total sales between 50 and $60 million. This is more than doubled out of 2018.
And while it's too early to share with you.
The allstate or for probably.
All right or will be with you shortly.
At launch than.
Right.
It's a bounce back at the same state.
Can I hope you sign.
We are starting.
I'd like to dial the M or.
And also.
I wanted Walmart dot.
I will naturally is happening.
And.
Over the brown.
Revenue.
Okay.
Through the rest of year.
There's a bit of background noise I could you said when one time please.
Okay and held at.
Brown.
In seem very strong growth in.
Right and what company our U.
And for natural.
Source.
Our.
Third would you on our last call.
Thank you you will be any listen only mode and the call is being recorded.
A record year.
Right.
I had approximately double that of 2018.
<unk>.
<unk> revenue.
We have scaled to new ingredients into this segment this year.
One of these has already shown.
Yeah.
And the other will.
Before year end.
Okay.
Our products that had been selling for over a year.
In this segment.
We are delivering over.
50.
Annual.
We have become the leading supplier.
<unk> of natural.
Sustainably sourced ingredients.
<unk> into the flavor and fragrance industry.
And our very pleased with a deeply strategic relationships we have.
With Firmenich and cheaper.
The two industry leaders.
And also our ongoing relationships.
Takasago Assaf.
Our strategy.
Partnering with industry leaders.
And delivering on their strategy to source natural.
Yeah, that's sustainable ingredients.
<unk> has resulted in us becoming.
The leading supplier of these ingredients in the.
With every ingredient we introduced.
We see the same pattern.
Our consumer.
The man in the.
And large global brands drive the.
We're seeing the same results with our sweetener business.
Pure.
Which is fermented.
Right.
A natural zero calorie.
Zero Glycaemic.
Non GMO.
That tastes great.
Well no.
You bet or.
Yeah.
We are on track to be the lowest cost producer.
[noise].
As the world's leading.
Yeah.
Natural zero calorie.
This is similar.
As to what we've achieved across the rest.
Of our ingredient portfolio.
Each time, we apply our leading.
It's.
We create bigger.
We're winning products that have the potential to.
Some of the world's leading.
And health issues.
Yeah.
We are focused our business development efforts during.
First half of the year.
On bringing together.
The consumer.
Goods companies.
With our target consumers the millennials.
Yes.
I would call this the sweet Revolution.
From a series of events across the U.S.
And fighting entrepreneurs.
A breakout brands for healthy living.
And social media Influencers in categories.
Fortys.
Yeah.
The fitness.
Traditional news media.
And importantly.
Ceos and R&D.
Of the well.
Global consumer.
Thanks.
Yes.
We have engaged well.
Food network personality.
Simon.
Yes.
Hi, Jim.
<unk>.
<unk>, who has partnered with us at restaurants.
Just your rating multi course meals.
In pure.
Yes.
Alongside Michelin chefs.
And.
Beard winters.
As consumers want you.
To reduce their sugar.
Concluding when they're eating out at restaurants.
Not just at.
The commentary teams, we've worked with in New York New Orleans.
<unk>.
In Austin and L.A.
<unk>.
I have not only.
The challenge to work with our sweetener.
They've delivered results that are so good.
We are starting to drive.
Into their menu.
These.
Yes.
Our sweeper has also attracted the attention of the American diabetes.
We introduced at their annual scientific sessions.
15000 researchers.
Clinicians.
And health care professionals.
In San Francisco this.
Our sweetener.
That is already grass.
By the FDA.
Okay.
<unk> has also now been approved by their.
I was honored to.
The American diabetes.
And the joined the 88 Executive Committee.
And also to be the executive chair.
One of their premier event in.
In one country.
Toward the cure.
On May Threerd 2000.
Hi, I'm looking forward to continue.
Our efforts together.
Together.
We are committed to a healthier and more sustainable.
It's exciting to see the response.
From our business to business customers to all our.
<unk> zero calorie sweetener.
Less than a year.
We have over 100 food and beverage companies.
Actively formulating their products.
Pure.
Inside.
Companies in every category.
You are looking to convert to our.
Beverage.
Speaking.
Yeah.
Hi, Gary.
[noise].
And your attrition.
We are selling.
Our fourth 2019.
<unk>.
I would have.
Started taking orders for our 20.
20.
Okay.
We have a blockbuster.
For the sugar reduction.
The world is demanding.
We are ramping.
So quickly.
We believe.
We are now.
More fermented zero calorie natural sweetener.
Than anyone else.
And we are just.
Starting.
We are experiencing significant.
From all other sources of.
As our first wave of.
We are also experiencing significant momentum.
As a key solution for the sugar reduction strategy.
[noise].
Of large medium sized.
[noise].
Our ability to successfully scale.
Sustainable ingredients and products that consumers love.
And that are healthier for.
It's becoming more noticeable to consumers.
And investors.
We have been particularly.
By growing investor awareness.
And.
And synthetic biology.
During this year, we saw successful IPO is like beyond.
Yes.
With the reported first half margin that was about half of hours.
Cymer.
When its last.
Funding round in December .
First of 2018.
Raised 400 million.
And as reported by Forbes.
Capital raise of chartered.
$50 million.
In spite gingko buyer works with its valuation.
Now.
$4 billion.
This is.
Good news for the future of our sector.
And the health of our.
It stands for.
Our investors.
We are the most advanced company in this sector.
With better technology.
Nine products commercialize.
Okay, and three new consumer brands that are tracking to be leaders and their categories.
Not surprisingly.
Despite.
Our prior non filing and non.
Clients.
Amorous has raised about $200 million this.
Yes, we've used these funds to help pay.
Over $90 million.
That.
The fund our.
And to continue our investment in our technology.
Well, we want to.
And our industry leadership.
The business results speak for themselves.
We are delivering.
And the fastest growing.
The largest absolute revenue.
Yeah.
The biggest decline and operating losses.
Within our sector.
Toward that end.
Yes.
And on our last call.
As I mentioned that we continue to refine the business.
The focus it on.
What we do best.
One area.
Where we have invested about $15 million this year.
Okay, and direct cash costs on projects.
Such.
HM Ocean vitamins.
As for the technology is.
Very well.
But the products no longer.
Strong strategic.
Fit in our long term.
[noise].
Our goal.
Just to monetize.
Programs.
We are pulling it upfront royalties.
While trading off a longer term opportunity.
Our earnings.
Future.
Yes.
We have agreed.
In terms.
With the.
And on our.
Program.
And our in advanced discussions.
With DSME.
Regarding the H. ammo development.
We expect a.
You agreements.
This year.
These agreements will result in about $20 million of.
Annual collaboration.
For the next several years.
And slightly more than $10 million upfront cash.
Okay.
We received.
This year.
[noise].
We are trading more cash upfront.
For a reduction.
In long term war LT.
Down to about 10% of sales.
Long term.
These changes significantly reduce our cash.
Okay and provide the support to increase our.
Right.
In our core.
Flavor and fragrance.
Ingredients.
Clean beauty.
And can adenoid ingredient.
<unk>.
And our consumer businesses.
The combination of the restructuring of this collaboration agreements.
With our long term partner.
Reduction and onetime expenses.
That are connected to our.
Financings at our accounting issues.
Okay, and the actions you'd want to and his team have taken to reduce.
Our cost of goods.
Is resulting in a.
All of over $40 million.
To our cash.
Okay and improvement to our EBITDA.
At our current.
<unk> annual revenue.
In summary.
Yeah.
This is.
$20 million annually.
Right and reduced cash.
And from the restructuring of the jumbo and vitamin.
$12 million annually.
From the elimination.
<unk> costs.
<unk>.
Related to our onetime.
And financing activity.
During 2019.
And a 10 million dollar improvement.
In cost of goods.
From the restructuring.
And of course.
Hi agreements.
With our Spanish.
Yeah.
He has some supply agreement.
For Farnesene.
And from.
The brought us to sell.
Our can happen towards developing.
In progress has been.
And exceeding our.
And we are now on track to commercialize.
Yes.
Two.
Cannabinoids in 2020.
Subject to legal and regulatory.
<unk>.
This is.
Significant progress.
From our initial.
One of one molecule in 2000.
Yeah.
Yeah.
And we believe.
Places us as the leaders in the production of high value.
Hi, guys.
Purity and quality production.
Sustainably sourced.
Kevin.
Yes.
We've also.
Some significant challenges.
The third quarter.
And with one of our debt holders.
Our challenges with the step holder started when our S. Three.
He became.
As the result of our non.
Clients.
Financial filings.
<unk>.
Back in April .
[noise].
This challenges related to the CVI Heights convertible.
Payment default.
[noise].
With that we disclosed in our 10-K.
We've been actively working with the board.
Phil the agent insider.
The source some of the funds necessary.
Pay down the slowdown.
And also are talking to other parties.
This process has taken longer than we expected.
Since the insider has been conducting due diligence.
From.
Which was slowed during the August .
Holiday season.
At this point.
We have received.
Cross default.
From mostly all of our other holders.
[noise].
It is unfortunate we cannot avoid this.
Okay and come to terms with CVI.
That would be fair.
Yes to all.
Our equity shareholders.
So we expect.
Close.
And are committed to a solution.
Before I turn the call over to toward.
I'd like to note a couple of upcoming filings we plan.
To do.
Over the next couple of weeks.
Or so.
And to help answer and advance any questions you may have.
[noise].
Due to our.
We expect a registration.
<unk>.
Resulting from our.
Our employee stock.
Grants for 2019.
We have essentially been frozen.
For many months.
So we'll be filing an essay registration.
<unk>.
Covering.
Employee options.
Our first use another.
Or employee stock.
Purchase.
[noise].
[noise].
And we also plan.
File an S. One registration statement.
As required by the agreements associated.
With our recent.
This will also give us the needed flexibility.
The fund business.
Continue.
And cleaning up our balance sheet to remove.
I am honored.
[noise].
Let me now turn over to you.
<unk> for an operational update and outlook.
Okay.
Thank you.
Good afternoon, everyone.
Let me start.
Summary for our production results.
For the first half.
Yeah.
2000.
Right.
We delivered.
<unk>.
Sustainable.
Fermentation.
And bottom.
For a total product quality.
14.
Yes.
On this.
This is the highest number.
Products, we've ever made in our history.
And I am pleased.
With the solid.
Four months.
Our process development.
Yes.
Supply.
In production.
Teams.
And our CMO.
This is a testament to our ability.
The scale production up multiple from in Asia.
On.
Ron.
Our commercial.
[laughter].
Stay.
On execution.
Yes.
Despite the recent.
And finally.
And funding.
<unk>.
These products into.
Before.
Labor.
Yeah.
Okay and fragrance ingredients.
For products 14 beauty.
And our zero calorie.
We for men.
These products.
Two different contract.
Any facts.
Sites.
In Brazil.
Let me also provide an update.
[noise].
Honor.
Products since our last call.
We just to lever.
Our first.
You product.
2019.
This is a new.
For for Maneesh.
Yeah.
In fact, our first.
Hey for these products.
Our production.
Good bye.
Eight.
Keep.
We remain on track to de lever.
Our second new.
40 year.
Fourg EBITDA during.
The.
Fourth quarter.
<unk>, which will.
Leading natural flavor.
This puts us on.
With our stated goal of delivering.
Due to three new.
For.
Looking at our second half of the year.
We are on track to Delever over.
Perhaps.
Tom.
Product.
<unk>.
Which is.
And with our.
How did that.
50 million.
<unk> revenue.
Guidance.
For 2000.
Would you seem to more comp.
And.
Volume would represent about.
Percent growth.
Now over to.
<unk>.
We believe.
2000.
18.
It's volume represents more than doubling of revenue.
As a result of the.
Your body.
I'm proud of.
40.
2000.
<unk>.
Right now.
[noise].
I would expand on our activities.
Two.
[noise].
The lever on our.
Thousand.
19 product.
Let's take a deeper look at the production.
And for our.
Sector.
It seems.
Yes.
Our production facility in North Carolina.
I believe a record.
We're squarely.
[noise].
Back to back.
Q1.
Into.
<unk>.
Okay.
Thousand.
Right.
During.
Fine.
Correct.
Ross.
Yes.
And capacity.
[noise].
That increased our.
Throughput by.
From the.
2000.
Thanks.
We are now.
Beating.
The new set of.
And that will add another.
30.
And productivity.
Bye.
Yeah.
The fourth quarter.
[noise].
The impact.
If you retain door Dorian.
And other factors feed costs on production shortfalls in.
<unk>.
But our team.
We remain confident that we.
You are on track to Delever.
Total.
Yes.
Whaling growth.
Eight.
And over.
2000.
[noise].
By the end of.
2000.
As I shared with.
Before.
[noise].
Let me also update you on that program.
I noted.
For.
<unk>.
In both the second.
Third.
As for our.
Dinner production.
Where we have been running our second production campaign.
2000.
We are ahead of our technology.
In the second half.
2000.
Right.
We had.
Expect.
<unk>.
Two to.
Default volume.
<unk>.
I'd now comparing our production.
From the first half to.
Second half.
<unk> thousand.
Right.
We can.
I wanted.
By the actual improvement was actually.
Despite.
<unk>.
Paul.
Our product.
[noise].
The only sugarcane the.
Giro.
Sweetener.
And as John mentioned.
Or.
[noise].
We have over.
100 active formulations.
With that.
And.
[noise].
Okay.
Taste.
And performance.
He's brought.
<unk>.
It is truly.
On.
Yeah.
What we have delivered is.
While maintaining the best days.
Yes.
<unk>.
Okay and quality.
Yes.
In the.
Now, let me switch over to.
The.
Yes.
<unk>.
Our non-GAAP .
Yes.
Cost of goods sold.
All forward.
First half.
29 million.
Our financial overview, we shared.
Well this malians.
What's caused by.
Two extraordinary.
The.
<unk>.
About half of it.
In higher upfront.
<unk>.
Gain.
<unk>.
Then or.
Our first.
In 2019.
This.
<unk> costs were charged.
<unk> cost.
Salt.
In additional.
All this work.
Helped us improve.
And simplified.
The process, which is now resulting in.
Despite.
Ballpark.
EBIT improvement I mentioned.
Before.
<unk>.
The second factor.
[noise].
<unk> has to do with.
<unk> costs.
There's a higher see about.
Where do result of are higher than.
Planned product volumes.
CMO contract terms.
And.
For these reasons, we implemented a new.
Commercial contract with our largest.
CMO.
Does that better.
And our cost.
With quality.
DVD.
<unk>.
We have now implemented these new.
And as a.
We.
Expect to see.
The 30% unit.
In five of our.
Yes.
By year end.
Yes.
Our team is on track to de lever on.
[noise].
Volume.
While also ensuring our gross margin.
Yeah.
Despite.
The five.
<unk>.
The five.
The extent level.
As mentioned.
Before.
We are.
Three many proud of our.
I've seen during.
This first half of the year.
And we already are.
On a.
Second half.
Finally.
Let me close with an update.
Yes.
On our future production.
And.
Yes.
Now.
All the.
<unk>.
Place, where our specialty.
In.
And have broken ground.
In Q3.
[noise].
The facility to.
Before the operational.
In Q1.
2021.
Obviously facility will allow us to.
Batch.
Five products at.
Yes.
This plan would be in Brazil.
The world.
Second largest.
Smell in by Robert.
Which is that raised.
No problem.
Yes.
This plan will be 100% owned by armor.
<unk>.
And have been designed to meet our future.
Production.
And.
Ports most of our.
Reported net.
Next three years.
Thanks.
As we noted in April .
We entered a long terms.
<unk>.
Hi.
<unk>.
For this plant would raise.
<unk>.
The world's largest.
Just sugar producers.
Which will reduce our.
And ensure the.
Quantity of non.
DML.
So.
And finally.
Right using an address we'll evaluate production opportunities related to the zero.
Carlos.
Such.
And our separate from the current.
<unk>.
Especially at the.
Yeah.
Glad dimension.
Before.
[noise].
Now.
I will turn to call over to John .
<unk>.
[noise].
Thank you Eduardo.
I'm happy.
To report that our 10-K is on trial.
And that we're completing.
Ups to regain climbing.
Yes.
By filing our two.
10-Q.
This was no easy task.
With two audit firms.
Quickly engagement on.
Set up.
The business transactions and.
On the.
Statements in a very.
I was curious.
Oh, sorry.
To Buck with a lot of hard.
And long hours by them and our team we got a.
I'd like just.
<unk>.
Thanks.
Yeah.
And all together as a.
Yes.
Well no surprise.
Preliminary financial results for the first half of 2019.
And in my discussion.
Okay.
I will refer mostly to round.
Millions of dollars.
<unk>.
Our GAAP revenue for the first half.
2019 was $77 million.
Okay.
$33 million.
<unk>.
For the same period in 2018.
Now.
Summary of the first and second quarters of 2019.
GAAP revenue.
For the.
Yeah.
First quarter.
$14 million.
Product sales.
12 million.
Collaboration revenue.
2 million.
<unk>.
Life.
And royalty revenue of 118.
Thousands though.
<unk>.
This compares with.
Quarter.
2000.
Team GAAP revenue of $18 million with.
Sales of.
5 million.
<unk>.
Collaboration revenue.
5 million.
And.
And royalty.
Revenue of 8 million.
Yeah.
[noise].
The decline in total revenue from the year ago period.
It's primarily.
The result.
The significant vitamin C. royalty.
Earned.
First quarter.
2018 compared.
No such comparative revenue.
Earn.
And from quarter 3000 bite.
[noise].
Yes.
non-GAAP .
Gross.
Bob.
Which was a loss of 4.8 million.
In the quarter compared with non-GAAP gross.
Gross profit of 14 million for the first quarter 2018.
[noise].
Okay.
In addition.
To the 8 million.
Dollar.
During 2019 that had water referred to just know materially.
[noise].
2018 benefited from significantly higher revenue.
Positive and the positive impact of.
Yeah.
Sales.
[noise].
General and administrative.
<unk> expenses were $28 million compared.
$18 million for the first quarter.
2018.
This increase reflects higher headcount to support our.
Yeah.
Our investment in the Biosite.
Its business.
<unk>.
Yeah.
Yeah.
I went.
Yeah.
For.
Fees due to.
Expenditures.
<unk>.
Related to resolving our.
Yes.
Research and.
<unk> expenses of $18 billion.
Yeah.
The first quarter 2000, my team were consistent with that.
For 2018.
Same quarter.
Turning now.
Second quarter of 2000.
90.
<unk>.
GAAP revenue was $63 million.
Product sales.
Yeah.
12 million.
Brad.
And collaborate.
Collaboration revenue.
Of 10 million.
<unk>.
Yeah.
Right.
Ppas and royalty revenue of 41.
As John .
Earlier mentioned.
The royalties.
Benefited from the sale of our boy vitamin E. royalty.
DSMB.
<unk>.
This past April .
These results compared with quarter to 2018, GAAP revenues of 15 million.
Consisting of product sales of 7 million.
And.
<unk>.
Collaboration revenue of approximately.
non-GAAP .
So.
But 52.5 billion compared with non-GAAP gross.
Gross profit.
<unk>.
11 million for the second quarter of 2018.
During the second quarter 2019, we posted positive EBITDA.
Approximately 2 million consistent with that.
We had previously noted.
As our believing we may have.
Positive EBITDA.
Yeah.
A couple.
The borders on fiscal 2000.
<unk>.
Right.
Sales.
General and admin.
Next administrative.
<unk> expenses were $31 million.
<unk>.
Compared.
19.
<unk> million for the same second quarter 2018.
Yeah.
The increase.
The continuation of the Q1 business drivers, reflecting higher headcount.
<unk>.
To support our.
[noise].
And our.
Business.
The continued what types.
Then for the professional fees.
Necessary for resolving our noncompliance does.
Research and.
<unk> expenses of 19 billion for the quarter compared to 16 billion from same quarter.
2000.
<unk>.
Subsequent to the second quarter close we have.
Separately.
Accreted over $60 million of additional.
<unk>.
To support our continuing working capital.
<unk>.
This has mostly been.
From long term investors, who have been supporting the company and remain very committed to our.
Continued.
[noise].
Having not compliant with our risk.
The filings made it very challenging.
We continue to fund.
Its growth while.
<unk>.
Maintaining our debt.
<unk>.
Becoming compliant will provide access.
The funding.
Better enabling.
To manage our debt and.
I was positioned and efforts to be.
The animal.
Profitable and growing.
Okay.
No and momentarily before I turn turn the discussion back to John I will address.
Yes.
We think is the obvious.
Question.
We trust.
Investors will appreciate that we now have filed.
Our 10-K.
For our 2017 and 18 financial statements.
[noise].
Shortly.
Forms 10-Q, four 2018 Q1.
Okay and Q2.
But to whats the imperative is to focus on.
Well, we do to ensure.
Does not have curriculum.
It is keenly at the forefront of our.
<unk>.
And we will engage you separately again.
Soon for that discussion.
At the moment.
As I like.
Say, we're focused on first thing first.
And those are the.
Next.
Ups, the complete and fire.
Our.
Forms 10-Q improved.
Pair for our quarter three.
[noise].
Thank you very much.
Yeah.
With that I'll turn the discussion back over to John .
Thanks, Jonathan and I really.
Yeah.
All the.
Have you and your team and.
Sleepless nights Youve.
You've all had.
How much appreciated.
Our business operations.
We are doing very well.
Okay.
And we are hitting our targets and executing on our commitment.
Double our recurring revenue.
Well.
She anyway.
And to exceed expectations for our collaboration partners and overall.
Technology performance.
Now I'd like to now.
What we've delivered.
So far.
And where we are headed.
We are about to become.
Hi.
With all.
Of our financial filings implants.
Good day that way.
Yes.
We have a new auditor.
The understands our business and is doing a great job.
We have the right controls and our correctly.
Yeah.
For our business.
Yes.
We had this kind of quality of service.
With Pwc.
As for most years of our history.
And believe we are getting.
Back to that way of.
There is no change.
To our business quality.
The cash we generated or the transactions we enter.
Into during the last several years.
Okay.
There have been many adjustments to how these were.
For.
Between the interest to the personnel.
And the balance sheet.
For 2000.
17.
In 2000.
In.
Okay.
We are on track to exceed.
Yeah.
850 million in.
For 2019.
Oh well over.
100.
30% growth.
And over.
For 2000.
Yes.
And we expect.
Recurring.
Opponents.
<unk>.
Of the revenue to maintain.
At this level of growth.
For the next.
Several years.
We have already.
It's much more recurring revenue year to date and all of last year and will more than double our recurring revenue for this year.
For over 2000.
Yes.
We are on track to deliver more than 60% gross margin for the year on a guidance of 55.
60.
5%.
We have scale and our delivery to new molecules this year and continue on track.
[noise].
For two to three new molecules a year.
Okay.
You go back to our history.
We have not had a.
Molecule launch since 2012 every one of our molecules continues to grow.
At double digits.
And has.
Very strong and strategic.
In the portfolio of our customers.
And or the relationships we have.
And our consumers.
We are on track the scale.
Two new can Avenue OID molecules in 2000.
20, double what we said we would do.
Our can Ave, it's program is exceeding.
Yes, we are on track to be a leader.
So in a growing industry.
That has.
The potential to transform over the counter treatments.
For pain management.
And suite.
[noise].
All of which.
So aging.
In the world.
Yes.
Okay and must have a replaced.
And for opioids.
So that is truly sustainable and.
We have taken.
Actions to reduce our cash.
Okay, and improve our EBITDA by over $40 million.
Annually.
Yeah.
Based on our current revenue levels.
We have closed over.
Our $200 million of new.
Year to date.
And have the commitment of our long term investors to continue.
For Amherst to be the leader.
In.
Biology.
[noise].
Biossance continues to deliver.
<unk> industry leading growth.
And we are introducing two new.
<unk>.
This year.
And with pipe.
It's already introduced.
Ken.
In the.
End of.
September .
And pure.
Coming very soon.
[noise].
We will announce before year end.
Another.
Great through brand.
Okay.
In partnership with one of the leading.
Models.
And entrepreneurs in the.
To introduce clean ingredient.
Just a beauty.
The more.
Rob.
I.
Very exciting to see.
Yeah.
A lot.
Very accessible.
Entrepreneurs.
Influencers and models.
Wanting to partner with us.
The build brands.
Set truly aren't making a difference there clean.
And they give the consumers what they.
And they make a positive.
At a different.
Yes.
[noise].
And last but not.
[noise].
We have delivered.
One.
Positive EBITDA quarter.
Okay, and we have the possibility of a.
And positive EBITDA quarter.
This year.
Yeah. So.
We expect recurring revenue growth to continue at current levels for the next few years.
While continuing to.
Our gross margin.
And reduce our cash burn we continue to expect positive EBITDA in 2000.
20.
Building on the operational momentum.
We.
<unk>.
In 2019.
We have built.
One of the fastest growing brands and clean.
And the fastest growing.
Sweetener brand in the.
And we are.
Standard Center.
For the best performing and.
As baby skin care products, you can buy.
The combination of our relationships.
And partnerships.
[noise].
With the world leaders.
In our.
Businesses target markets.
Our world, leading synthetic biology.
And the leading brands.
So that we're building.
And executing on.
It is all delivering.
And on our mission of making the.
Healthier.
No one molecule at a time.
I really appreciate you all participating in our call.
Okay, and Jake I'd now like to open up.
Two questions.
Yes.
We will now begin the question answer session. Tasking question you May have press Star then one on your Touchtone phone.
If you are using.
Speakerphone, please pick up your handset before pressing the keys to withdraw your question. Please press Star then to at this time, a pause momentarily to assemble our roster.
First question comes from Amit Dayal.
H.C. Wainwright. Please go ahead.
Thank you.
Good afternoon, everyone.
<unk>.
John just to begin with the compliance.
Aspect.
Landing on becoming.
By October seven to <unk> on October seven.
I expect us to be.
Before October seven.
Got it thank you.
[noise].
And in relation to this heights debt situation can you talk about what are the next steps.
Your negotiations or discussions with them.
We are in this is an active active discussion rights on.
I'm pretty sensitized to it.
But I can tell you that were.
We have.
Access to the necessary funding.
And we are in process of ensuring its a good and safe funding for our company and resolves the heights needs.
[noise].
And then.
What do you mind sort of refreshing for everyone what qualifies.
Sure.
No you're regarding your revenue.
Products all product lines.
Its a.
Its a.
Every.
The thing we supply.
Product in.
That has.
A multi year.
Contract.
So it's all of our ingredients.
It's the.
[noise].
Yes.
I think that's it really all the ingredients in the brands.
The in the recurring revenue.
What's not in.
Or any other collaborations.
As for.
Our.
And.
Where the supply side, our long term contracts every one of our.
Our supply agreements in the ingredient side.
Our typically 10 year long.
Supply agreements.
That have Irene you cycle automatically built that.
Got.
[noise].
Okay.
[noise].
And then just a question on you know what you're seeing.
Or what do we should be sort of looking as dry it was.
For.
You know.
Now, let's that would fill the gap slobs sort of.
40 million that you received from the vitamin E exit in the second quarter this year.
No going into next year, what would be somewhat good drivers that could you comment sort of.
Yes.
[noise].
Or even exceed that 40 million for us.
Yes.
We already have that.
Replace.
Because of this significant increase in it can happen would payments for next year.
So we've already more than made up the difference.
<unk>.
On the vitamin D going into next year.
Yes.
I.
We're not we're not in the world of providing.
Guidance going into next year, but.
Yeah.
I would say at a minimum next year will be.
Well into the 200 million and I'd love to get to the quarter billion Mark.
<unk>.
Okay and revenue next year and again all of that.
What we have.
In place.
And that's what we're focused on really a underpinning.
And more importantly, more most.
Importantly, having the production capacity in 2020.
The deliver that.
Got it.
[noise].
You know in the context of guidance I'll be maintaining sort of the 150 million by 1009.
We are I think it.
In the call I was.
A pretty.
Pretty explicit to have chosen the warrant.
Because we are already.
Hi.
For a well above that 150 marks there were.
Right.
Shifting that you exceeded but we don't want to put another number out there so we'd like to keep the current number out there.
Okay and know that we are already.
Okay.
Tracking well above the 150.
Yeah I missed.
And just one last question on the.
Outstanding Shareco.
Cash and debt.
You have <unk> other than this afternoon.
The filings have done they could you give us a sense of you know maybe are and you know.
The.
Yeah, we expect a with.
Our third quarter earnings call.
To be in a position to.
A little more detail around that because I think at that point well have clarified.
I kind of what I'd call the net debt for the year.
Because as you know we've got some outstanding.
Okay.
Yet that.
As being.
I used to.
To convert warrants the equity so once that is cleared up which I expect to be.
Around.
The third quarter earnings call, we should be able.
The provide good guidance as to where we are and make transparent.
Our outstanding and net debt for the year.
Understood.
That's what I've known thank you so much.
I appreciate.
Thanks submit.
It's being on the call.
The next question comes from Graham.
Tanaka with Tanaka Capital management. Please go ahead.
Thank you very much.
For for this conference call.
Oh longtime coming and good to hear.
Lot of moving parts and I just was wondering if you could start with.
Leveraging on leveraging off what was just.
Cost about the balance sheet.
Looking into next year.
Okay.
Or maybe longer term what are your.
Plans for.
Our net debt.
And if you could incorporate your.
Cash flow.
And capex needs for this next year versus.
This year.
It would be helpful.
But.
[noise].
Hi, Graham as always thank you for beyond the call and as always you asked a question that make us deeper than we'd like on the call right. So thank you for that.
Look I think.
As we go into next year, we see the business.
Generating cash to support itself.
We obviously.
You know.
Our investing in the technology I think that changes we've made to the jumbo in the vitamins agreement.
Really shifts what we've been doing on the technology. The one thing to think about as we've been investing about 70 million a year.
Since 2000.
10 on the technology and that investment that annual investment has very little to do.
Products that we.
We make and ship everyday really has to do with pipeline.
And I think we're now at a point where.
Okay.
Especially with the significant performance on cannabinoids.
And what's happened in the reset of the current agreements and then some expansion we're doing with our FNF partners in a very focused way.
It really getting rid of.
That loss and that will have.
By loss I mean, the investments we've been making.
Technology.
<unk>.
No I have a material.
The effect on our cash burn that plus the.
Growth going into next year really says the business.
Yes cash flow positive from an operating.
So the real cash.
Beyond that as Capex.
And the Capex needs is really connected to.
[noise].
Continuing.
The.
The new plant right, we've been funding that plan out of our own.
And we expect to continue that.
Going into next year, how much is that that's probably somewhere around 60 to 70 million.
Of Capex.
And that Capex.
We actually have a couple of our partners.
Who are deeply dependent on the ingredients, we make better in current discussions with us about actually.
Funding.
Plant.
<unk>.
We have.
Other sources, but that's probably the more likely route that we take a to enable us to fund the plant. So if we're successful with that and operationally.
We do what.
We.
We plan on doing I think we end up going into next year.
We're starting to generate cash for the business rather than putting it in.
And then for the rest of this year.
We still have some.
We still have some.
Some cash to fund right, so even though the fourth quarter is very strong.
The third quarter was also very strong from a growth perspective, you can imagine that the working capital needs.
As you're doubling your product.
Production every quarter.
It is.
So I would say.
We still have cash needs.
The fund the.
Ending this year.
Going.
Into next year, we should end up.
Positive position and then during next year, the big real a need for capital.
It's really around Capex for the plan.
[noise].
So I hope those moving parts are helpful.
Yeah and I do.
I think it's at the grid up can you talk about maybe a little bit about.
Capital.
Efficiency and.
What kind of revenues you can generate for.
Per se.
$50 million.
As a capex or $60 million.
As a capex.
My understanding is you.
Thank you.
Or.
Good.
Higher value.
Yeah.
Part of our price per pound or per kilogram.
Value products and I'm, just wondering if that means your capex.
<unk>.
He will be lower per dollar.
Yeah, I mean, that's all connected to the a the gross margin and.
I can tell you that based on the mix we have.
Right now.
And our current cost of goods.
For the products in the portfolio.
The return on that 70 million.
<unk> is about 12 to 18 months.
And that's again really simple the way we look at it is.
Dollars generated per kilo of production and then the revenue the annual revenue from that.
Yeah.
And this is product revenue not.
And the a single plat 70 million dollar investment has capacity to generate about $300 million of product revenue. So I think those are the two key metrics, what's the cash.
It's about a 12 to 18 month.
Okay and then.
And what is the revenue you generate revenue is about 300 million.
In annual if the plant is.
Fully sold.
Okay.
The Big picture, what was a comparison versus the.
The that I mean.
Some of them more commodity.
Yes.
What would that ratio.
[laughter].
And.
Well, that's a great.
It's it's about a five to six year payback, which is pretty much what a.
Typical chemical plant is right so.
Call it five to six year payback and revenue.
Do you think about revenue.
And about.
20 to 30 million.
So call it 30 million on the high end.
Annual revenue off of that same investment right 70 million of investment.
Again about 30.
A quick could be higher if you include.
Value share in that it could be as high as 40 million.
<unk>.
Annually.
And again about a five to six year payback.
On the.
I think a shift real quickly to the CBD.
The opportunity.
Does the.
Doubling.
Of the number of.
The two products from.
Mean that Youre, a little more optimistic about the milestone payments that of the 300 million.
Total.
For the.
Three year project.
Thanks.
We are we're not changing.
We're not changing guidance right I think we've said 50 million on the low end 100 million on the high end.
And for Us.
[noise].
Cannabinoids.
Smiles.
For next.
I think we feel very secure about the low end.
Sure.
And I think we could be somewhere between the low end to high.
Well, we'll see how the.
The year goes.
What we're very confident as now that we've got we're actually making these.
Molecules.
It's really about ensuring we have the production capacity at the right location.
And to make the kind of volume that we want to make a and with all the regulatory complexity. That's what the team is focused on.
I think the other thing I'm very optimistic about is.
Yeah.
The fact that Lavanya is brought in.
And I really experienced.
Okay.
That really understands the market and we're pioneers in the.
And the Canadian.
Good.
When the nature of conversation in.
The depth of discussion and knowledge.
Yes.
<unk> has.
Dramatically so.
They know.
Which.
Stake itself.
At what value.
And what we're seeing is this new molecule.
Yes.
It's actually a breakthrough.
It's one that's.
Rarely available we had a hard time, finding samples just to be able to validate.
What we were making.
And it's one that's much higher value.
When we first started out within.
We said publicly our first target which were CBD.
And again, we're not going to.
We're not going to make public the second one.
But.
That that for US was a huge breakthrough that we had a second molecule.
We are producing it now.
Now it's the second molecule that's transformational for the can happen, which sector and one that our partners are extremely familiar.
[noise].
I just.
Yes.
Did you just.
Say that you.
Do you have produced.
Both molecule.
We have produced both molecules successfully produced both molecules.
We probably have done more than just that but I.
Were not going to.
And by the way we're talking about.
In the lab right, we're now focused on.
Where do we go and how do we scale it but right now.
We successfully produced.
And have demonstrated the full pathway to make exactly our targets at the level of purity that we need.
We're very excited.
Yes.
Putting pressure on Chuck correct.
How much of the effort is now.
Yes.
Achieved relative to having a full production molecule.
In terms.
Right.
I think for the second one I'd say over half the efforts done and now the effort is really Chuck.
But he is going to break on this molecule until the beginning of next year and on the first molecule I'd say probably 20.
The percent of the.
Yeah.
So we have a waste to go.
Okay and developing the pathway.
It's pretty clear what we need to do so we're not too worried about that but in the second molecule.
The breakthrough molecule where.
We're well.
Well to commercialization.
Well.
Covenant.
Commercialization on a first on the second molecule and the first molecule your 80% there.
No. The second one which is really the first when we had made public were about 20% there the second.
That we're now producing the one that were.
Sure.
Well on our way.
And I'll, probably sometime for other people just wanted to roughly when do you think you might be able to deliver.
Commercial production.
Each.
To the two molecule.
Both molecules will be doing commercial production in 2000.
Right.
And for one of them, we could be as early.
And plan on being as early as a midyear.
That's.
The first one that you.
EBITDA.
<unk>.
I'm not going to say that because again one of the things that happened is.
We were surprised by.
Well again the value in great partners is.
They typically have.
On molecules more than we do so the partner.
Identified a molecule.
It's a molecule.
With that.
Quickly.
We were able to make.
And that molecule is significantly more valuable.
Then.
<unk>.
CBD.
So it is likely and were.
Okay.
We are performing better without molecule than CBVA.
It is likely that'll be the.
Yeah.
<unk>.
To.
And again all of that assuming that the legal and regulatory.
It is.
<unk>.
Safe and able to.
It is going to mark.
Yeah.
But.
Thank you very much on.
[noise].
Thanks.
Again it yeah the question.
Please.
Press.
[noise].
Star.
Then one.
<unk>.
The next question comes from.
Randy Barron with Pinnacle.
Please go ahead.
Hi, good afternoon.
I think with all the focus on the delayed financing I just wanted to start with you Eduardo.
[noise].
I think the significance of your accomplishment of taking cost out.
It is.
Really kind of.
With everything that's going on so just.
And do you and your.
Okay.
Hi.
You're welcome I have a few just administrative questions and then.
Abroad.
And.
Positive EBITDA in the second quarter, just because we haven't seen the 10-Q's yet.
Does that.
[noise].
Include or exclude the onetime Odyssey.
It includes the onetime audit fee. It is adjusted EBITDA. So it does not include non cash like the stock comp component.
Got.
It.
Which is I'm happy to hear that.
Related to that.
You mentioned kind of 12 million of costs year over year for some reason I thought.
That this thought it was costing even more.
Oh.
What is the total.
But this audit has.
And.
Is it 12 million and what do you expect your audit costs to be for calendar call. It 2020 in a normal basis, assuming no issue.
Yeah.
Yeah I mean.
Randy I.
I'll take a guess at the 2020, just because we haven't gotten into those discussions with the auditor and my guess will be based on.
And what are.
I had been.
Yes.
Prior to this mess.
Okay, John and I.
You know knowing to.
The current audit firms I don't expect it to be a.
Significantly greater than that.
Regarding.
The amount.
<unk> costs.
Direct cost where the.
Firms.
Yes.
Firms because.
Obviously, we had KPMG, which became a disaster and then the.
Yes.
It's probably in direct cash.
Somewhere around 7 million.
And the Delta between the seven in the 12.
Those are all the legal fees and outside contractor and consulting fees.
We've had to pay.
Right.
For support and getting.
Everything cleaned up right so.
So I just wanted to make a distinction around those numbers.
What do I see a normal.
Full year audit fee.
Look I think a normal years around wanted to have to 1.7 million, that's kind of what we've been a incurring.
And what we expect to get back to.
[noise].
<unk>.
I noticed when you talked about financial as expected. The next few weeks, yes, one et cetera.
You didn't mention the.
The next 10-Q.
When do you expect that to be filed will that be the normal.
Whatever 40 560 days after the quarter.
Or.
What you expect has yet to a third Q, we're going to be right back on normal schedule.
Great.
And then just one last.
High level question I.
The DARPA grant is expiring if it hasn't already.
What's what's.
And this is not only talked on this call, but what is the outlook for the.
The military.
In their interactions with emerus. Thank.
I'm actually at the White House.
Yes.
On Monday, having exactly that discussion, there's actually a strategic initiative.
Oh that the White house.
Yes.
And the military is very interested in.
And around synthetic biology, which is builds on the work they've been doing so.
I'll have a better view after.
You're right.
The current.
DARPA program.
Is over this year I think we still.
Yeah.
Some revenue.
Yeah, I know, we booked some revenue year to date and I think we have some left.
Fourth quarter.
I'm not really sure but it is definitely over this year.
Oh, and then just one last question.
The.
$10 million of accelerated.
Is that.
Shifting with DSME.
Was that.
How much of that was already included in the 150 million of guidance for this.
It was not it was not actually.
Oh and by the way I wanted to clarify.
<unk>.
With that 10 million, it's actually more than 10 I I'm.
Again guiding low because.
Until it's done it's not done a and the 10 is already related to another agreement which is actually.
The fine so we're actually.
And with DSME, we've agreed on the basic terms and now we're in process of.
[noise].
Getting agreements.
You know.
And then with you.
We've done a two part D. A one was restructuring the old deal.
The second is.
Adding two new vitamins.
The two new vitamins are in process, we'll have it.
Fleet.
By the end of the fourth quarter.
And the restructuring of the old agreement is already.
Right.
And you know if I were to tell you.
The real dollar realization the front end dollar.
And both of these.
It's probably more around.
15 level could be 15, or 20, but 10 is already.
The place based on what we've already negotiated.
And.
And that 15 to 20 would also be a calendar 2019, if it came to pass or is that spread over the.
Into 2020.
I wanted to be careful Randy itself.
Now, we'll all be 20.
Oh, I'm, sorry, that'll all be 2019, but here's the issue.
Which is why I didnt included and we're not actually talking about it as part of revenue.
I don't know.
So how it'll be recognized.
[laughter].
So.
Payment not a problem restructuring.
Yeah, well make all that transparent.
So whether it goes to revenue.
Or whether it's the first.
I don't know, yes, that's not only part of what John it than in the.
Teams will figure out.
So its cash again.
Yeah.
I don't know about.
<unk>.
Okay wasn't in our.
Your.
Understood.
<unk>.
And then Barra Bonita.
The.
The new Brazil plant you mentioned you.
[noise].
May funded with your partners down there.
Obviously broke ground already.
When.
When do you think you'll know.
Is it imminent is.
Hi, Matt you're going you're negotiating.
When are we going to know how that's being.
[noise].
Okay.
Yes, actually two different things so survival data is the plant Bonita is owned by.
A joint venture between Sheldon co.
[laughter].
<unk>.
I hope Anita.
Well Hasan has.
Very long term strategic supply agreement with us.
Supply all of our utilities.
Came Sarah.
The first plan is the 100% hours.
And when I said partner.
We're actually in discussions with a few of our flavor and fragrance partners.
That are interested in.
In financing that plan so they can ensure.
Our security of supply.
There's a second.
Going on which is actually related to.
A second factory not in the short term, but probably a.
A 2021 factory connected to sweetener.
And that is one.
We're pacing.
It has an option.
And to fund that.
As part of a joint venture with us for.
I just wanted to give you a bit of the detail.
We've announced some of this stuff over the last.
Six to nine months, but it's kind of lost and all the.
Clutter out there and I just wanted to clarify for.
Okay. Thank you very much.
Thanks.
The next question comes from.
Honestly.
Seaport global.
Now please go ahead.
[noise].
Hey, John I'm, good afternoon to you and the rest of your team I. Appreciate you guys taking my.
My question.
My My question just centers on.
Cannabinoids.
[laughter].
You would.
Mention though the legal on the regulatory backdrop.
In an earlier answer and then I'll be honest with you.
<unk>.
I don't quite understand the legal and the regulatory backdrop for.
[noise] biosynthetic Cbds Jose I was hoping you could educate me a little bit on that and it's particularly a particular again the.
The language that we saw from Mitch Mcconnell recently, where he.
Seems to throw the word him in front of every type of communication on.
CBD and directing the F.D.A.
To get some some guidelines in place.
So.
Are you guys confident the biosynthetic CBD could be produced didn't marketed across the U.S. at the federal level or would this be more of a state.
I State thing if you can just give me.
Insight into that it'd be really helpful.
Yeah.
Great question and by the way Oh.
Thank you.
Before.
The efforts you've made to help us understand the industry more and all that you publish I think you do a great job.
Keeping.
In the industry.
Aware so thank you for that.
Look I.
I.
I put this out really as a cautionary note.
Not because I see today.
Any.
The difference in the regulatory.
And whether it is biased.
Synthetic were.
So I just want to first make that point this is not about.
You know, there's a different regulatory risks that I'm actually seeing it's more about.
As you've seen like.
Yeah, a any interstate commerce.
Other than topical for cosmetics.
There is always questions about rice I, just don't want to.
I don't want to mislead I want to make sure people know that.
We have that in mind.
We're focused on.
We think of the market as global and that's another point.
Yeah its global.
We have manufacturing axis.
Simpler and plan to make.
It outside the U.S. not just in the U.S. and.
And then in the us.
Again, we don't.
We don't see a separation and we are.
Very engaged obviously with a policymakers just to ensure.
Just like in all of our other businesses.
That there is.
A fair treatment.
Okay and their risk technology neutrality for what source of materials are out there and that the focus really needs to be.
The safety of the consumer.
Okay and availability of supply.
At a cost it makes sense for world that needs it and that's our focus and it's not again driven by.
Difference.
Today.
We're seeing.
A a regulatory approach.
That differentiates.
Thank you John I appreciate it.
<unk>.
Pleasure.
I think we're done.
Good question.
[noise].
Okay. Thanks, so much thanks, everyone for being on the call I really appreciate.
In closing I'd like to thank everyone for the support during what has been.
The most difficult time in our history, we are pleased to putting this time behind us.
We know that there's a lot of work to do I respect all the folks who have been putting in the hours they.
And I'm also very committed to ensuring this is a.
Non repeat for us and that we we manage our business in a.
Safe and healthy way.
And that we ensure that.
We're working closely with our accounting partners Tomorrow, we'll be presenting at the.
B. Riley FBR consumer media conference, where we'll share more in our progress and share.
On our amorous own brand, so I hope you're able to be there whether it's thanks again.
And a great afternoon to.
Morning.
The conference has now concluded. Thank you for attending today's presentation you may now disconnect.